Extending previous observations reporting higher levels of CK18 (M30 and M65) in NAFLD subjects compared to healthy subjects [25,29,46] and even more in steatohepatitis [41], this is, to our knowledge, the first demonstration indicating that CK18 (M30) predicts FLI-suspected NAFLD, except for a very recently shown relationship of CK (M30) with the FLI as a continuous parameter [47], and that CK-18 (M65) predicts 10-year CVD risk independently of FLI if the SCORE2 algorithm is used for CVD risk stratification purposes. Here, KRT18 is linked to metabolic dysfunction-associated steatotic liver disease.